| Zheng, Gang PH |
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps |
|
|
| Recruiting | 2 | 120 | RoW | 300mg/600mg of TQH2722 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Rhinosinusitis | 10/25 | 11/25 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
NCT04171037: Optiflow THRIVE for Delivery of Oxygen to Patients During Total Intravenous Anesthesia While Undergoing Radiology Procedures |
|
|
| Completed | N/A | 110 | US | Oxygen Therapy, supplemental oxygen therapy, Questionnaire Administration, Optiflow THRIVE | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Obstructive Sleep Apnea | 06/24 | 06/24 | | |
| Zhang, Hua |
NCT03476083: Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission |
|
|
| Recruiting | 4 | 280 | RoW | Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily., HBIg 200 IU im for infants in the group B, HBV vaccine 10 ug im for all infants | New Discovery LLC | Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia, Chronic Infection | 05/21 | 05/24 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
AK0529-2007, NCT06775405: A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants |
|
|
| Recruiting | 3 | 180 | RoW | AK0529, Placebo | Shanghai Ark Biopharmaceutical Co., Ltd. | Respiratory Synctial Virus Infections | 08/25 | 09/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | 2 | 261 | RoW | Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005） | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Ankylosing Spondylitis | 02/25 | 10/25 | | |
NCT06451640: A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps |
|
|
| Recruiting | 2 | 60 | RoW | 210mg of TQC2731 injection, 420mg of TQC2731 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Chronic Rhinosinusitis With Nasal Polyps | 05/25 | 02/26 | | |
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps |
|
|
| Recruiting | 2 | 120 | RoW | 300mg/600mg of TQH2722 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Rhinosinusitis | 10/25 | 11/25 | | |
NCT06617936: Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. |
|
|
| Recruiting | 2 | 35 | RoW | neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy, surgery, Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar), Standard Treatment | Hua Zhang | Unresectable Non-small Cell Lung Cancer | 08/25 | 09/27 | | |
NCT06657391: Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia |
|
|
| Recruiting | 2 | 396 | RoW | recombinant humanized anti-CD25 monoclonal antibody | Rongrong Liu | Transfusion Dependent Thalassemia | 09/27 | 09/27 | | |
NCT06709859: Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC |
|
|
| Not yet recruiting | 2 | 30 | RoW | Afatinib plus chemotherapy as conversion treatment | Shandong Public Health Clinical Center | Carcinoma, Non-Small-Cell Lung | 05/26 | 12/27 | | |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
NCT06036927: A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Recruiting | 2 | 80 | RoW | TQC2731 injection, TQC2731 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Sinusitis, Nasal Polyps | 07/25 | 09/25 | | |
| Recruiting | N/A | 1500 | RoW | | Huashan Hospital, China Alliance for Rare Diseases, National Center for Neurological Disorders (China), China myasthenia gravis collaborating group (CMGCG) | Myasthenia Gravis | 02/34 | 01/35 | | |
| Recruiting | N/A | 120 | RoW | Functional anterior temporal lobectomy (FATL), Anterior temporal lobectomy (ATL) | First Affiliated Hospital Xi'an Jiaotong University | Temporal Lobe Epilepsy, Open Surgery, Minimally Invasive Surgery | 09/24 | 09/25 | | |
| Recruiting | N/A | 50000 | RoW | comprehensive management algorithm for preventing mother-to-child transmission of HBV | Nanfang Hospital of Southern Medical University, Chinese Foundation for Hepatitis Prevention and Control, Tigermed Consulting Co., Ltd | Hepatitis B, Chronic, Mother to Child Transmission | 06/25 | 12/25 | | |
| Xu, Jian |
NCT05830500: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma |
|
|
| Recruiting | 4 | 360 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Medullary Thyroid Cancer | 06/27 | 12/28 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
| Recruiting | 2 | 146 | RoW | Sirolimus, rapamycin, Placebo | Chinese SLE Treatment And Research Group, Beijing Municipal Science & Technology Commission, North China Pharmaceutical Group Corporation | Systemic Lupus Erythematosus | 10/24 | 05/25 | | |
NCT05242588: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Non-radiographic Axial Spondyloarthritis | 04/23 | 06/23 | | |
NCT06140966: Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 2 | 54 | RoW | Daratumumab, Darzalex, Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone, Baycadron, Cisplatin, Platinol, epirubicin, Pharmorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, Alkeran, ASCT, autologous stem cell transplantation, bortezomib, Velcade | Wuhan Union Hospital, China | Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma | 10/26 | 10/27 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
NCT05227677: Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 200 | RoW | GA guided anti-diabetic therapy adjustment, current guidelines to adjust treatment | Asahi Kasei Pharma Corporation | Type 2 Diabetes Mellitus | 08/24 | 12/24 | | |
NCT05888545: Clinical Study on a Novel Anti-adhesion Barrier Film |
|
|
| Recruiting | N/A | 1176 | RoW | anti-adhesion diaphragm | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Intrauterine Adhesion | 12/24 | 12/24 | | |
LEFAZAREM, NCT04737343: Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis |
|
|
| Recruiting | N/A | 114 | RoW | Leflunomide, Tuoshu for commericial name, Azathioprine Tablets | Chinese SLE Treatment And Research Group, Shanghai Zhongshan Hospital, Affiliated Hospital of Jilin University, Changchun,China, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Anhui Medical University, Beijing Shijitan Hospital, Capital Medical University, The Affiliated Hospital of Inner Mongolia Medical University, The First Affiliated Hospital of Kunming Medical College, Sichuan Province People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University | ANCA Associated Vasculitis, Maintenance Therapy | 11/24 | 12/24 | | |
NCT05866029: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture |
|
|
| Recruiting | N/A | 2478 | RoW | Denosumab, Teriparatide | Peking Union Medical College Hospital | Osteoporotic Fractures | 09/26 | 09/26 | | |
| Recruiting | N/A | 2000 | RoW | | Peking Union Medical College Hospital | Anti Phospholipid Syndrome | 12/26 | 12/26 | | |
| Cheng, Yongjun |
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
